Keyword Connections

Remission Induction

Journals

0

No Journal Connected

Research Groups

0

No Research Group Connected

Bibliographies

26

1 Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis

2 [Discontinuation of immunosuppressive and immunomodulatory drugs in connective tissue diseases]

3 Certolizumab pegol for induction of remission in Crohn's disease

4 What happens after complete withdrawal of therapy in patients with lupus nephritis

5 Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunochemotherapy. Histiocyte Society

6 Remission and withdrawal of therapy in lupus nephritis

7 Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis

8 Longitudinal follow-up of patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis

9 [Discontinuation or tapering strategies of biologics in rheumatoid arthritis in remission]

10 Early Improvement in Work Productivity Predicts Future Clinical Course in Depressed Outpatients: Findings From the CO-MED Trial

11 Infectious complications during remission induction therapy in 577 patients with acute myeloid leukemia in the Japan Adult Leukemia Study Group studies between 1987 and 1991

12 Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management

13 Prognostic factors of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children: report of the Japan Histiocytosis Study Group

14 Early normalization of Quality of Life predicts later remission in depression: Findings from the CO-MED trial

15 Changing Crohn's disease management: need for new goals and indices to prevent disability and improve quality of life

16 A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490)

17 Current evidence supporting mucosal healing and deep remission as important treatment goals for inflammatory bowel disease

18 Treatment Targets in Inflammatory Bowel Disease: Current Status in Daily Practice

19 Adalimumab induces deep remission in patients with Crohn's disease

20 Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease

21 Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial

22 Regression of Hodgkin lymphoma in response to antiviral therapy for hepatitis C virus infection

23 Epidemiology of influenza A virus infection in patients with acute or chronic leukemia

24 Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed

25 Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis

26 Transdermal nicotine for mildly to moderately active ulcerative colitis. A randomized, double-blind, placebo-controlled trial